NEW YORK, NY, Oct. 21, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: T...
Tauriga Launches CBD Infused Tauri-Gum™
CBD INFUSED TAURI-GUM™ IS TAURIGA’S FIRST GUM PRODUCT
Tauriga Sciences would like to thank all its loyal shareholders as well as welcome new shareholders. Management believes 2021 has the potential to be an exciting year for the Company. Over the course of the past two years, Management has been working diligently to both restore and create shareholder value for the Company’s shareholders.
The Company has previously indicated in press releases and SEC Filings, its intent to pursue a major potential acquisition(s) and or product development initiative(s). Over the past year, the Company has also been contemplating opportunities involving product development and commercialization initiative(s).
One such opportunity on which the Company has acted (initially disclosed during December 2018), involves the Company entering into the cannabidiol (or “CBD”) infused chewing gum product business for retail customers and as a pharmaceutical gum for relieving nausea symptoms for chemotherapy patients. These opportunities are more fully described above and in prior press releases. This CBD infused chewing gum product has been branded under the following name: Tauri-Gum™. See also our periodic reports filed by us with the SEC for a more complete description of our business and material agreements that we have entered into. The Company now has developed 5 proprietary CBD gum flavors including;
The Company also developed an immune booster Pear Bellini flavored chewing gum containing 60mg of Vitamin C and 10 mg of Zinc.
Shop Now At taurigum.com
The Company currently has equity stakes in three exciting growth companies. As previously stated, the Company holds an equity position in privately held Aegea Biotechnologies. The Company also holds an equity stake in Serendipity Brands, one of the fastest-growing ice cream company that is now sold in nearly 30,000 stores. The Company has long held a large position in Vista Gen Therapeutics, a biotech company with several developing drugs in the depression and social anxiety space.
Based on feedback and testimonials from Tauri-Gum™ customers, the Company developed a proprietary stronger gum formulation consisting of nutriceuticals including CBD for aiding patients with nausea symptoms primarily caused by chemotherapy. The Company retained and has filed a provisional patent for its formulation and is currently working with the FDA in preparation for clinical trials. The nausea relief market is estimated to be $7 billion dollars annually.
The Company is also working on a collaboration with Aegea Biotechnologies to develop next-generation virus tests including for COVID-19. The Company also has an equity stake in Aegea Biotechnologies. Aegea Biotechnologiescurrently holds 11 issued US patents including its Switch Blocker and Primer Switch patents that are currently generating revenue in the oncology liquid biopsy space.
NEW YORK, NY, Oct. 21, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”...Read More
NEW YORK, NY, Oct. 15, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company...Read More
The Blister Pack Design has been Updated for All 6 Tauri-Gum™ Flavors and Now Includes Halal Certification Icon, QR Code, and Other Features NEW YOR...Read More
Fully committed to commercializing innovation to enhance personal wellness, improve our environment and create lasting shareholder value.